Kura Oncology Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Plans
During the three months ended September 30, 2024, certain of our officers adopted written plans for the purchase or sale of our securities as noted below:
| Trading Arrangement | |||||
|---|---|---|---|---|---|
| Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares to be Sold · Expiration Date | |||||
| Stephen Dale, M.D., Chief Medical Officer | Adoption | September 17, 2024 | X | 772,834, and RSU net shares | December 16, 2025 |
| Brian Powl, Chief Commercial Officer | Adoption | September 18, 2024 | X | 113,977, and RSU net shares | December 18, 2025 |
| Thomas Doyle, Senior Vice President, Finance and Accounting | Adoption | September 17, 2024 | X | 125,597 | December 18, 2025 |
- Intended to satisfy the affirmative defense of Rule 10b5-1(c)
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
In addition, our officers (as defined in Rule 16a-1(f) under the Exchange Act) have entered into sell-to-cover arrangements adopted pursuant to Rule 10b5-1 authorizing the pre-arranged sale of shares to satisfy our tax withholding obligations arising exclusively from the vesting of shares of restricted stock. The amount of shares to be sold to satisfy our tax withholding obligations under these arrangements is dependent on future events which cannot be known at this time, including the future trading price of our shares. The expiration date relating to these arrangements is dependent on future events which cannot be known at this time, including the final vesting date of the applicable shares of restricted stock and the officer’s termination of service.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.